noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

University of Massachusetts Amherst

Faculty Forum on Building Equitable and Inclusive Classrooms Set for[...]
FEMA - Federal Emergency[...]

Two Weeks Left to Apply for FEMA Assistance after Tropical Storm Arthur
Dell Technologies Inc.

Notice of Proposed Sale of Securities (Form 144)

Healthcare

Lake Street Capital Markets LLC

09/17/2026 | Press release | Distributed by Public on 09/17/2026 09:01

Kyntra Bio, Inc. (KYNB) - Initiation of Coverage

Lake Street Capital Markets Analyst, Daniel Brims, Ph.D., initiated coverage of Kyntra Bio, Inc. with a BUY rating and price target of $41 (KYNB-$41). Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

‍

Want to stay up-to-date with the latest at Lake Street? Subscribe to our mailing list!

NameEmail Address

Thanks for joining our mailing list.

Oops! Something went wrong while submitting the form.

Attachment

Lake Street Capital Markets LLC published this content on September 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 17, 2026 at 15:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format